GlaxoSmithKline Reports Positive Results For Malaria Treatment

Features Dow Jones Newswires

GlaxoSmithKline PLC (GSK.LN) Monday announced positive results for its malaria treatment tafenoquine in Phase III testing.

Continue Reading Below

The drug giant said a single dose the treatment, used to prevent relapses of Plasmodium vivax malaria, reduced the risk of relapse in patients significantly more than a placebo when given alongside a 3-day blood-stage chloroquine treatment.

Shares at 1113 GMT, down 4 pence, or 0.2%, at 1,695 pence valuing the company at GBP83.3 billion.

-Write to Rory Gallivan at; Twitter: @RoryGallivan

(END) Dow Jones Newswires

June 12, 2017 07:29 ET (11:29 GMT)